- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer or soft tissue sarcoma harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.7MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 831KB)
Larotrectinib – March 2024
Larotrectinib: Capsule 25 mg (as sulfate), Capsule 100 mg (as sulfate), Oral solution 20 mg per mL (as sulfate), 50 mL, 2; Vitrakvi®
Last updated
30 May 2025